Medicare覆盖范围，癌症复发和确切的科学：改变游戏规则

精确科学的OnCodetect™测试可确保医疗保险的覆盖范围，标志着大肠癌患者和个性化医学的关键时刻。

Medicare Coverage, Cancer Recurrence, and Exact Sciences: A Game Changer

Medicare覆盖范围，癌症复发和确切的科学：改变游戏规则

Big news in the fight against colorectal cancer! Exact Sciences just got the green light from Medicare for its Oncodetect™ test. This means earlier, more personalized insights for patients. Let's dive into what this means for you.

反肠癌斗争的重要新闻！精确的科学刚刚获得了Medicare的绿灯，以进行OnCodeTect™测试。这意味着对患者的更早，更个性化的见解。让我们深入了解这对您意味着什么。

What's the Buzz About Oncodetect™?

OnCodetect™的嗡嗡声是什么？

Oncodetect™ is a molecular residual disease (MRD) test. Basically, it's like a super-sensitive detective for cancer. It hunts down tiny traces of cancer cells that might be left behind after treatment. Think of it as a high-tech tool that helps doctors spot recurrence way before traditional methods, potentially up to two years sooner than imaging alone. Pretty slick, huh?

OnCodetect™是一种分子残留疾病（MRD）测试。基本上，这就像一个癌症的超敏感侦探。它可以追捕治疗后可能会留下的癌细胞的微小痕迹。将其视为一种高科技工具，可以帮助医生在传统方法之前发现复发的方式，可能比单独成像要早起来长达两年。漂亮，吧？

Medicare Says Yes: A Huge Step Forward

Medicare说是：向前迈

The Centers for Medicare & Medicaid Services (CMS) has granted Medicare coverage for Oncodetect™ for patients with stage II, III, and resectable stage IV colorectal cancer. This coverage applies to serial use over five years in adjuvant and recurrence monitoring settings. This is a massive win because it makes this cutting-edge technology accessible to more people who need it. It's a big deal for the over three million Americans eligible for MRD testing across multiple solid tumors.

Medicare＆Medicaid服务中心（CMS）已为II，III期和可切除的IV期结直肠癌的患者授予了OnCodetect™Medicare覆盖范围。该覆盖范围适用于五年来辅助和复发监控设置的串行使用。这是一个巨大的胜利，因为它使得需要它的更多人可以使用这项尖端的技术。对于有资格在多个实体瘤中进行MRD测试的超过300万美国人来说，这是一件大事。

Why This Matters

为什么这很重要

Here’s the deal: early detection is everything. The Oncodetect™ test tracks up to 200 ctDNA variants, helping oncologists make informed decisions during critical treatment moments. Brian Baranick, Executive Vice President and General Manager, Precision Oncology at Exact Sciences, said it best: this coverage expands access to earlier, more personalized insights.

这是交易：早期发现就是一切。 OnCodeTect™测试轨迹多达200个CTDNA变体，帮助肿瘤学家在关键治疗时刻做出明智的决定。精确科学精确肿瘤学的执行副总裁兼总经理Brian Baranick说，这是最好的：这种覆盖范围扩大了对早期，更个性化的见解的访问权限。

The Science-y Stuff (But Not Too Much)

科学的东西（但不是太多）

The Oncodetect™ test isn't just some flash-in-the-pan technology. It's backed by solid clinical validation, including studies like Beta-CORRECT and Alpha-CORRECT. These studies confirm the test's ability to predict outcomes across different stages of colorectal cancer. Plus, it integrates seamlessly with the ExactNexus™ platform, making it easy to use alongside other Exact Sciences tools.

OnCodetect™测试不仅仅是一些闪光技术。它得到了坚实的临床验证的支持，包括β-校正和α-校正等研究。这些研究证实了该测试能够预测结直肠癌不同阶段的结果的能力。另外，它将与Exterrexus™平台无缝集成，从而易于与其他精确科学工具一起使用。

Looking Ahead

展望未来

Exact Sciences isn't stopping here. They're pushing for Medicare coverage across other solid tumor indications, aiming to bring the benefits of MRD testing to even more patients. It's all about improving outcomes and giving people a fighting chance.

确切的科学并没有停止这里。他们正在推动其他实体瘤指示的医疗保险覆盖范围，旨在将MRD测试的好处带给更多患者。这一切都是关于改善结果并为人们提供战斗机会。

The Bottom Line

底线

Medicare coverage for Oncodetect™ is a game-changer. It means more people have access to advanced technology that can detect cancer recurrence earlier and help doctors make better treatment decisions. It's a win for patients, a win for science, and a win for the future of cancer care.

OnCodetect™的Medicare覆盖范围是改变游戏规则的。这意味着越来越多的人可以使用先进的技术，这些技术可以更早地检测到癌症的复发并帮助医生做出更好的治疗决定。这是患者的胜利，科学的胜利，也是癌症护理未来的胜利。

So, what’s next? Keep an eye on Exact Sciences. They’re not just sitting back; they’re actively working to make cancer screening and diagnostics better for everyone. And that’s something to smile about, wouldn't you agree?

那么，下一步是什么？密切关注确切的科学。他们不只是坐下来；他们正在积极努力为每个人提供更好的癌症筛查和诊断。这是值得微笑的，您不同意吗？